The cost effectiveness of screening newborns for congenital adrenal hyperplasia.

Byung Kwang Yoo, S. D. Grosse

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVE: To assess the cost effectiveness of newborn screening for congenital adrenal hyperplasia (CAH) in the U.S. newborn population. METHODS: We constructed a decision model to estimate the incremental cost-effectiveness ratio (ICER) of CAH screening compared to a strategy of no screening. Two types of cost effectiveness analyses (CEA) were conducted to measure ICER as net cost per life year (LY): (1) traditional CEA with sensitivity and scenario analyses, and (2) probabilistic CEA. RESULTS: ICERs for (1) base-case analysis in traditional CEA and (2) probabilistic CEA were USD 292,000 and USD 255,700 per LY saved in 2005 USD, respectively. ICERs were particularly sensitive to assumptions regarding the mortality rate for the salt wasting type of CAH, in a range from 2 to 9%. The ICERs for best-case and worst-case scenarios were USD 30,900 and USD 2.9 million per LY saved, respectively. CONCLUSIONS: Using common benchmarks for cost effectiveness, our results indicate that CAH screening would be unlikely to be considered cost effective unless assumptions favorable to screening were adopted, although it could meet economic criteria used to assess U.S. regulatory policies. A limitation is that the analysis excludes outcomes such as correct assignment of gender and quality of life.

Original languageEnglish (US)
Pages (from-to)67-72
Number of pages6
JournalPublic Health Genomics
Volume12
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Congenital Adrenal Hyperplasia
Cost-Benefit Analysis
Costs and Cost Analysis
Benchmarking
Salts
Economics
Quality of Life
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The cost effectiveness of screening newborns for congenital adrenal hyperplasia. / Yoo, Byung Kwang; Grosse, S. D.

In: Public Health Genomics, Vol. 12, No. 2, 2009, p. 67-72.

Research output: Contribution to journalArticle

@article{ffcf7fa3fb0247b2acef0153414c7a73,
title = "The cost effectiveness of screening newborns for congenital adrenal hyperplasia.",
abstract = "OBJECTIVE: To assess the cost effectiveness of newborn screening for congenital adrenal hyperplasia (CAH) in the U.S. newborn population. METHODS: We constructed a decision model to estimate the incremental cost-effectiveness ratio (ICER) of CAH screening compared to a strategy of no screening. Two types of cost effectiveness analyses (CEA) were conducted to measure ICER as net cost per life year (LY): (1) traditional CEA with sensitivity and scenario analyses, and (2) probabilistic CEA. RESULTS: ICERs for (1) base-case analysis in traditional CEA and (2) probabilistic CEA were USD 292,000 and USD 255,700 per LY saved in 2005 USD, respectively. ICERs were particularly sensitive to assumptions regarding the mortality rate for the salt wasting type of CAH, in a range from 2 to 9{\%}. The ICERs for best-case and worst-case scenarios were USD 30,900 and USD 2.9 million per LY saved, respectively. CONCLUSIONS: Using common benchmarks for cost effectiveness, our results indicate that CAH screening would be unlikely to be considered cost effective unless assumptions favorable to screening were adopted, although it could meet economic criteria used to assess U.S. regulatory policies. A limitation is that the analysis excludes outcomes such as correct assignment of gender and quality of life.",
author = "Yoo, {Byung Kwang} and Grosse, {S. D.}",
year = "2009",
doi = "10.1159/000156115",
language = "English (US)",
volume = "12",
pages = "67--72",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - The cost effectiveness of screening newborns for congenital adrenal hyperplasia.

AU - Yoo, Byung Kwang

AU - Grosse, S. D.

PY - 2009

Y1 - 2009

N2 - OBJECTIVE: To assess the cost effectiveness of newborn screening for congenital adrenal hyperplasia (CAH) in the U.S. newborn population. METHODS: We constructed a decision model to estimate the incremental cost-effectiveness ratio (ICER) of CAH screening compared to a strategy of no screening. Two types of cost effectiveness analyses (CEA) were conducted to measure ICER as net cost per life year (LY): (1) traditional CEA with sensitivity and scenario analyses, and (2) probabilistic CEA. RESULTS: ICERs for (1) base-case analysis in traditional CEA and (2) probabilistic CEA were USD 292,000 and USD 255,700 per LY saved in 2005 USD, respectively. ICERs were particularly sensitive to assumptions regarding the mortality rate for the salt wasting type of CAH, in a range from 2 to 9%. The ICERs for best-case and worst-case scenarios were USD 30,900 and USD 2.9 million per LY saved, respectively. CONCLUSIONS: Using common benchmarks for cost effectiveness, our results indicate that CAH screening would be unlikely to be considered cost effective unless assumptions favorable to screening were adopted, although it could meet economic criteria used to assess U.S. regulatory policies. A limitation is that the analysis excludes outcomes such as correct assignment of gender and quality of life.

AB - OBJECTIVE: To assess the cost effectiveness of newborn screening for congenital adrenal hyperplasia (CAH) in the U.S. newborn population. METHODS: We constructed a decision model to estimate the incremental cost-effectiveness ratio (ICER) of CAH screening compared to a strategy of no screening. Two types of cost effectiveness analyses (CEA) were conducted to measure ICER as net cost per life year (LY): (1) traditional CEA with sensitivity and scenario analyses, and (2) probabilistic CEA. RESULTS: ICERs for (1) base-case analysis in traditional CEA and (2) probabilistic CEA were USD 292,000 and USD 255,700 per LY saved in 2005 USD, respectively. ICERs were particularly sensitive to assumptions regarding the mortality rate for the salt wasting type of CAH, in a range from 2 to 9%. The ICERs for best-case and worst-case scenarios were USD 30,900 and USD 2.9 million per LY saved, respectively. CONCLUSIONS: Using common benchmarks for cost effectiveness, our results indicate that CAH screening would be unlikely to be considered cost effective unless assumptions favorable to screening were adopted, although it could meet economic criteria used to assess U.S. regulatory policies. A limitation is that the analysis excludes outcomes such as correct assignment of gender and quality of life.

UR - http://www.scopus.com/inward/record.url?scp=58949100737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949100737&partnerID=8YFLogxK

U2 - 10.1159/000156115

DO - 10.1159/000156115

M3 - Article

VL - 12

SP - 67

EP - 72

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 2

ER -